EMA Recommends Eco-Friendly Inhaler for COPD
The recomposition involves replacing the existing gas propellant, HFA-134a, with a low global warming-potential (GWP) gas alternative called HFO-1234ze(E). The propellant is used for drug delivery and is not an active medicine.
AstraZeneca claims that the new propellant will lead to a 99.9% reduction in GWP and an 85% reduction in greenhouse gas emissions compared with current propellants. The company adds that its carbon footprint is similar to that of dry powder inhalers.
The reformulation was approved by British regulators in May and is currently under review in other countries such as China.
COPD is an umbrella term for a group of lung conditions, including emphysema and chronic bronchitis. Symptoms include shortness of breath, frequent chest infections, and persistent wheezing. Estimates suggest that around 36.5 million people had COPD in Europe in 2020, and that this number will increase to 49.5 million by 2050.
Trixeo Aerosphere and Riltrava Aerosphere have three active ingredients: budesonide, glycopyrronium, and formoterol fumarate dihydrate. Budesonide is a glucocorticosteroid that exerts rapid, dose-dependent, anti-inflammatory action on the airways when inhaled. Meanwhile, glycopyrronium is a long-acting muscarinic antagonist and formoterol fumarate dihydrate is a selective beta2-adrenergic agonist. Both result in bronchodilation.
The reformulation comes as the EU phases out high GWP gases for environmental reasons. The EMA reported that studies confirm the safety and efficacy of the reformulated medicine are equivalent to those of the currently approved product. The associated studies will be made available in the variation assessment report following the European Commission's final decision, which is expected in the coming weeks.
Annie Lennon is a medical journalist. Her writing appears on Medscape, WebMD, and Medical News Today, among other outlets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Treatment Considerations for End-Stage COPD
This transcript has been edited for clarity. Hi, everyone. Dr Chandrasekaran here, and today I'm going to talk about end-stage COPD (chronic obstructive pulmonary disease). We commonly diagnose COPD based off one of three things. One being imaging, showing emphysema or bronchitis; one being pulmonary function tests that can show obstruction; and one being symptom-based. Together, these help us to stage, define, manage, and treat patients with COPD. Once they do reach end-stage COPD, this becomes a healthcare burden associated with increased hospitalizations. We manage these patients by making sure they are on triple-therapy inhalers, including a LAMA (long-acting muscarinic antagonist), LABA (long-acting beta agonist), and inhaled corticosteroids. In addition, we can add theophylline or roflumilast to help decrease hospital readmissions. Chronic azithromycin therapy, 250 mg three times a week, has been shown to decrease shortness of breath and recurrent hospital admissions. Prior to starting this, sensorineural hearing tests along with QTc must be done to make sure that they are not increasing or addition, noninvasive ventilation can help these patients, as they do suffer from sleep-disordered breathing, and help decrease the hypercapnia that these patients face. Long-term oxygen therapy needs to be considered for end-stage COPD, along with lung volume reduction surgery in a handful of patients that do qualify and endobronchial valves in patients who have emphysema and qualify for these mechanisms.
Medscape
3 hours ago
- Medscape
When Medicine Meets Philosophy: A New SEC Series
Medicine and Philosophy, a new roundtable series by the Spanish Society of Cardiology (SEC) in collaboration with Madrid's Círculo de Bellas Artes, aims to facilitate discussions between medical, science, and humanities experts. The series, which took place in May and June, was recorded and can be viewed online at the SEC's channel. Organizers and Topics The Hippocratic Chapter of the SEC, along with organizers from the Círculo de Bella Artes, decided on three healthcare topics to explore in the series. The session titles were "The Doctor-Patient Relationship in the Era of Artificial Intelligence," "Who Wants to Live Forever?", and "Is Boredom a Medical Problem? AI in Medicine: Pros and Cons AI's role in medicine was the first session's focus. Panelists discussed how AI saves time by streamlining data interpretation, allowing more time spent with patients. Ironically, the extra time results in the expectation that patient load should increase. The importance of physician input in AI advancement for medical use, as well as educating future clinicians on AI, were discussed. A Long Life The concept of living a longer life was discussed in the second session. A balanced approach to the topic by medical professionals and philosophers created a crossover of biological facts with existential questions about the meaning of life. Is Boredom Treatable? The last session featured panelists talking about boredom, whether it is a medical issue, and the social and medical repercussions of labeling these normal emotional life experiences as treatable conditions. Were These Roundtables Successful? Yes. All sessions sold out and this success has prompted the organizers to brainstorm future topics for collaboration. Also, expanding this series outside of Madrid is a possibility. Bottom line: Viewing healthcare topics through scientific and philosophical lenses can foster thought-provoking discussions, as shown by the success of the Medicine and Philosophy roundtable series. The full list of panelists can be found on the Círculo de Bellas Artes page for the roundtable series.
Yahoo
5 hours ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
